REGEN BIOPHARMA, INC.: 10-Q/A filed 2021-12-22
What REGEN BIOPHARMA, INC. reported in its quarterly report amendment filed 2021-12-22 (fiscal Q3 2021): 26 published measures, 75 facts as tagged in accession 0001607062-21-000637.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-Q/A (quarterly report amendment)
- Filed
- 2021-12-22
- Fiscal period
- fiscal Q3 2021
- Accession
- 0001607062-21-000637 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGEN BIOPHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 1,433,656 | USD | |
| At 2020-09-30 | 123,189 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 13,845,341 | USD | |
| At 2020-09-30 | 7,458,187 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | -12,411,685 | USD | |
| At 2020-09-30 | -7,334,998 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 188,179 | USD | |
| At 2019-09-30 | 7,855 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -7,489,115 | USD | 91 |
| 2020-10-01 to 2021-06-30 | -5,380,566 | USD | 273 |
| 2020-04-01 to 2020-06-30 | 3,205,945 | USD | 91 |
| 2019-10-01 to 2020-06-30 | 2,211,567 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-10-01 to 2021-06-30 | -63,921 | USD | 273 |
| 2019-10-01 to 2020-06-30 | 18,645 | USD | 274 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 29,206 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 29,206 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-10-01 to 2021-06-30 | -47,900 | USD | 273 |
| 2019-10-01 to 2020-06-30 | -26,500 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-10-01 to 2021-06-30 | 300,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | -21,964,232 | USD | |
| At 2020-09-30 | -16,583,666 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 3,573,338,986 | shares | 91 |
| 2020-10-01 to 2021-06-30 | 2,608,298,343 | shares | 273 |
| 2020-04-01 to 2020-06-30 | 1,605,000,246 | shares | 91 |
| 2019-10-01 to 2020-06-30 | 1,359,014,732 | shares | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -42,491 | USD | 91 |
| 2020-10-01 to 2021-06-30 | -73,945 | USD | 273 |
| 2020-04-01 to 2020-06-30 | -16,336 | USD | 91 |
| 2019-10-01 to 2020-06-30 | -190,408 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 379,137 | USD | |
| At 2020-09-30 | 103,220 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 59,569 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 198,029 | USD | 273 |
| 2020-04-01 to 2020-06-30 | 81,343 | USD | 91 |
| 2019-10-01 to 2020-06-30 | 252,000 | USD | 274 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 13,845,341 | USD | |
| At 2020-09-30 | 7,458,187 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 100,223 | USD | |
| At 2020-09-30 | 110,486 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 185,466 | USD | |
| At 2020-09-30 | 103,192 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 14,254 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 15,893 | USD | 273 |
| 2020-04-01 to 2020-06-30 | 12 | USD | 91 |
| 2019-10-01 to 2020-06-30 | 10,354 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 3,780,195,788 | shares | |
| At 2020-09-30 | 1,605,000,246 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | 8,392,382 | USD | |
| At 2020-09-30 | 8,313,877 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-06-30 | -10,535,891 | USD | |
| At 2021-03-31 | -5,070,713 | USD | |
| At 2020-12-31 | -5,581,256 | USD | |
| At 2020-09-30 | -7,334,998 | USD | |
| At 2020-06-30 | -8,559,070 | USD | |
| At 2020-03-31 | -11,769,440 | USD | |
| At 2019-12-31 | -7,699,447 | USD | |
| At 2019-09-30 | -10,908,795 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -7,489,115 | USD | 91 |
| 2021-01-01 to 2021-03-31 | 442,183 | USD | 90 |
| 2020-10-01 to 2020-12-31 | 1,666,367 | USD | 92 |
| 2020-04-01 to 2020-06-30 | 3,205,944 | USD | 91 |
| 2020-01-01 to 2020-03-31 | -4,077,145 | USD | 91 |
| 2019-10-01 to 2019-12-31 | 3,083,375 | USD | 92 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | -7,489,115 | USD | 91 |
| 2020-10-01 to 2021-06-30 | -5,380,566 | USD | 273 |
| 2020-04-01 to 2020-06-30 | 2,564,755 | USD | 91 |
| 2019-10-01 to 2020-06-30 | 1,769,254 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-04-01 to 2021-06-30 | 24,157 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 108,821 | USD | 273 |
| 2020-04-01 to 2020-06-30 | 43,749 | USD | 91 |
| 2019-10-01 to 2020-06-30 | 205,994 | USD | 274 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-10-01 to 2021-06-30 | 82,273 | USD | 273 |
| 2019-10-01 to 2020-06-30 | 6,373 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-10-01 to 2021-06-30 | -10,263 | USD | 273 |
| 2019-10-01 to 2020-06-30 | 15,431 | USD | 274 |
Inspect the source
- Entity
- REGEN BIOPHARMA, INC. / CIK 0001589150
- Captured
- 2026-09-20T09:23:48.532Z
- SEC response SHA-256
0bbe246b6080c7701ba978807745a4ba9de62971ab4db32e8d3e2fa2c4f26a87
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001589150.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))